Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P20366 (substance P)
 21,176 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The enterochromaffin (EC) cell system is distributed throughout the entire gastrointestinal tract. Enterochromaffin cells are the major source of intestinal serotonin (5-HT), but separate subpopulations of EC cells may synthesize and store peptides as substance P (SP), motilin, and enkephalin as well. Of special interest is that 5-HT and SP, which may coexist in EC cells, have several functional similarities, i.e., inhibition of gastric acid secretion, stimulation of intestinal motility, and secretion of water and electrolytes. Carcinoid tumors are derived from the gut endocrine system. Depending on site of origin, carcinoids are divided into foregut, midgut, and hindgut derivatives with different clinical symptoms. A common biochemical feature of midgut carcinoids is the production of 5-HT and SP. Histochemically, midgut carcinoids are characterized by the argentaffin reaction--a direct reduction of silver salts owing to 5-HT. Specific antisera for the immunocytochemical demonstration of secretory products are available as well. Despite their relative infrequency, carcinoids are the most common small intestinal tumors. The common appendix tumors generally have a benign clinical course, whereas the small intestinal tumors have different growth patterns and frequently metastasize with increasing size, and may thus give rise to the carcinoid syndrome (diarrhea, facial flush, right-sided cardiac valvular disease, and asthma). Carcinoid symptoms first appear when hepatic inactivation of 5-HT is exceeded, unless the carcinoid has an extraintestinal localization, for example, ovarian lesions may elicit symptoms in the absence of hepatic disease owing to direct secretion into systemic circulation.(ABSTRACT TRUNCATED AT 250 WORDS)
J Cardiovasc Pharmacol 1985
PMID:Serotonin and carcinoid tumors. 241 66

Serotonin (5-HT) and substance P (SP) were assayed in peripheral blood in patients with known midgut carcinoids and hepatic metastases. All patients had supranormal basal levels of 5-HT and SP. The clinical and hormonal response was evaluated by two provocation tests, pentagastrin (PG) injection or calcium infusion. Pentagastrin caused flushing and gastrointestinal symptoms and elevated levels of circulating 5-HT, but not of SP. Pretreatment with a 5-HT2 receptor blocking agent (ketanserin) alleviated gastrointestinal symptoms but had no influence on either 5-HT release or PG-induced flushing. Calcium infusion induced carcinoid symptoms in only two of six patients, which were associated with elevated 5-HT levels (whereas elevated SP levels were seen in only one patient). We conclude that 5-HT is important for the development of gastrointestinal symptoms but not of flushing. Ketanserin may alleviate gastrointestinal symptoms but does not influence PG-induced release of 5-HT. Substance P and 5-HT do not seem to share a common release mechanism. It appears that PG testing is superior to calcium infusion as a provocative test in patients with the carcinoid syndrome.
J Cardiovasc Pharmacol 1985
PMID:The pentagastrin test in the diagnosis of the carcinoid syndrome. 241 67

During open-heart surgery, myocardial biopsies were obtained before the start of extracorporeal circulation (from the right auricular appendage) and after weaning from the pump (from the right atrium), and processed for immunocytochemical demonstration of substance P- and leu-enkephalin-immunoreactive nerve fibres and for electron microscopy. Substance P-immunoreactive nerves were seen around blood vessels, between myocardial cells and forming large glomerulus-like loops, but were not numerous. Leu-enkephalin-immunoreactive nerves were very sparse. We therefore believe that both nerve types primarily are modulatory axons. In the post-weaning specimens, nerves of both types were more numerous (attributable to the different site of biopsy), and no change was seen in the immunofluorescence reaction. The ultrastructure (all types) of nerve terminals was well preserved, although myocardial damage was obvious in many specimens. Cardiac nerves, including peptidergic nerves, thus seem to be relatively resistant to ischaemia, hypothermic chemical cardioplegia and reperfusion injury.
Scand J Thorac Cardiovasc Surg 1986
PMID:Substance P- and leu-enkephalin-immunoreactive nerves before and after myocardial ischaemia, hypothermic chemical cardioplegia and reperfusion injury during open-heart surgery. 242 45

The most important central autonomic pathways in the control of arterial blood pressure are the baroreceptor reflex pathway and descending pathways from the hypothalamus. Central neurotransmitters in these pathways are L-glutamate, substance P, norepinephrine (NE), gamma-aminobutyric acid, epinephrine, neuropeptide Y, and acetylcholine. At peripheral autonomic neurovascular junctions, there are prejunctional alpha 2- and dopamine-2 receptors, which inhibit NE release, and beta- and serotonin receptors, which stimulate NE release. Postjunctional alpha 1-receptors open sodium channels, open calcium channels via phosphoinositol release, and release intracytoplasmic calcium. Postjunctional alpha 2-receptors, which are extrasynaptic, inhibit adenylate cyclase and also open calcium channels. In animal models of hypertension, changes in alpha-receptor density have been reported. In spontaneously hypertensive rats, increased renal beta- and alpha 2-receptors, respectively, may enhance renin release and cause sodium and water retention. In experimental (renovascular) hypertension, vascular postsynaptic (vasoconstrictor) alpha 1- and alpha 2-receptors are increased. In both models of hypertension, beta-receptors are down-regulated. Selective alpha 1-antagonists, such as indoramin and prazosin, decrease arterial blood pressure by postsynaptic alpha 1-blockade; alpha 2-receptor inhibition of NE release is unaffected so that there is no beta-receptor-mediated tachycardia.
J Cardiovasc Pharmacol 1986
PMID:Alpha-adrenoreceptors in hypertension. 242 93

Reflex circulatory changes mediated by capsaicin sensitive cardiac afferent neurones were studied in anaesthetised, open chest dogs. Application of capsaicin to the epicardium of the left ventricle, either in single doses (0.01-100 micrograms) or by superfusion (20 micrograms X min-1), consistently resulted in dose related increases in blood pressure and heart rate. These responses were not affected by bilateral vagotomy but were abolished or reversed by bilateral sectioning of the upper thoracic (T1-T4) white rami communicantes and stellectomy. Injection of capsaicin (0.3-1 microgram X kg-1) into the left circumflex coronary artery caused either systemic hypotension and bradycardia (70.3% of experiments), a pressor response associated with tachycardia (13.5%), or a biphasic effect with an initial rise and then fall in blood pressure and heart rate (16.2%). With intravenous injections of capsaicin (3-5 micrograms X kg-1) the response was invariably cardioinhibitory and depressor. The reflex bradycardia and hypotension evoked with either intracoronary or intravenous injections of capsaicin were reversed after bilateral vagotomy to increases in cardiac rate and blood pressure. The post-vagotomy tachycardia occurring with intracoronary capsaicin could be abolished by beta adrenoceptor blockade with propranolol (0.5 mg X kg-1 iv), whereas ganglionic transmission blockade with pentolinium (0.5 mg X kg-1 iv) eliminated both the tachycardia and pressor effects. The results indicate that in the dog's heart capsaicin sensitive afferent neurones capable of affecting the circulatory system have both vagal and spinal sympathetic origin. It is suggested that capsaicin induced excitatory cardiogenic reflex is nociceptive in nature and may involve activation of substance P containing afferent fibres incorporated in cardiac sympathetic nerves.
Cardiovasc Res 1986 Dec
PMID:Cardiovascular reflexes mediated by capsaicin sensitive cardiac afferent neurones in the dog. 243 39

Administration of 6.5-pmol-6.5-nmol doses of substance P (SP) into the spinal subarachnoid space at T-8-T-10 in urethane-anesthetized rats increases both mean arterial pressure (MAP) and heart rate (HR) in a dose-related manner. However, in rats anesthetized with sodium pentobarbital, an increase in MAP is seen only at low doses of SP (6.5-65 pmol), while a biphasic response is obtained at 650 pmol and only a depressor response at 6.5 nmol SP. These responses also are accompanied by a tachycardia. Depending on the spinal cord level, cardiovascular responses of different time course and magnitude are elicited by SP. The amplitude of the increases in MAP and HR produced by SP (6.5 nmol) are: T-8-T-10 greater than T-1-T-3 greater than L-2-L-4 in rats anesthetized with urethane. In rats anesthetized with sodium pentobarbital, the decrease in MAP levels is greatest at T-1-T-3, while it is similar at T-8-T-10 and L-2-L-4 levels. The effects of SP on HR are more complex. The different cardiovascular responses obtained with the two anesthetics are not attributed to the relative depth of anesthesia but may be due to differential effects of the anesthetics on sympathetic nervous activity. The effect of SP on HR can be blocked by propranolol, but it remains unaffected by the surgical removal of the adrenal glands. We conclude that this cardiovascular response is most likely mediated by the postganglionic noradrenergic fibres and that adrenal medullary catecholamines are not essential. Using several inhibitors of endogenous mediators, two components to the spinal action of SP on MAP are made evident. The pressor response can be explained solely by the activation of sympathetic preganglionic fibres in the intermediolateral nucleus of the spinal cord, while the depressor response, in addition, may involve the release of a vasodilatatory substance in the periphery, the action of which persists in the presence of cholinergic, histaminergic, serotonergic, or opioid antagonists. Moreover, the adrenal glands are excluded as a possible source of this substance.
J Cardiovasc Pharmacol 1988 Mar
PMID:Studies on the cardiovascular effects produced by the spinal action of substance P in the rat. 245 19

This paper presents results on the function of the adrenal medulla, especially the influence of substance P (SP) on the cholinergic-adrenergic interaction. Interconnections between the function of SP and its role in the development and maintenance of hypertension as well as its role in stress and adaptation are investigated. Substance P acts only in situations with an increased nervous activity, for example, after stress-induced activation of the pituitary-adrenal and sympathetic-adrenal axis. Substance P normalizes stress-induced disorders by maintaining homeostasis in the catecholamine system. The basis of the antistress effect is the modulation of both biosynthesis and release of catecholamines in the adrenals. The homeostasis effect of SP, as well as the antistress effect do not require the complete sequence of the molecule. The N-terminal SP fragment is fully active and has no side effects.
J Cardiovasc Pharmacol 1987
PMID:Relationship of substance P to catecholamines, stress, and hypertension. 245 60

Substance P (SP) plays an important role in central nervous and peripheral blood pressure regulation. Its effects include modulating influence on the adrenergic system and inhibition of stress-induced plasma noradrenaline increase in animal studies. In patients with essential hypertension (n = 45, WHO stages 1 and 2) the SP-like immunoreactivity (SPLIR) was found significantly (p less than 0.01) lower (1.36 +/- 0.23 pg/100 microliters) than in 24 normotensive subjects (4.54 +/- 0.72 pg/100 microliters). Furthermore, the influence of a mental stress test on SPLIR was investigated in patients with essential hypertension (n = 11, WHO stage 1) and compared with nine normotensive subjects. Whereas in normotensive subjects plasma SP increased under a standardized mental arithmetic test (4.03 +/- 0.48 to 4.74 +/- 0.56 pg/100 microliters), in hypertensive patients a decrease of SP from lower baseline levels (2.85 +/- 0.54 to 2.57 +/- 0.54 pg/100 microliters) was demonstrated. The significantly different changes of plasma SP in normotensive and hypertensive subjects under mental stress conditions had the opposite direction in comparison with the adrenergic reaction [higher and prolonged increase of plasma noradrenaline (NA) in the hypertensive group]. Under antihypertensive drug treatment with prazosin (4.5 mg/day, n = 10) or with captopril (450 mg/day, n = 10) an increase of plasma SP was registered. The results support the participation of SP in the pathogenesis of human hypertension and in therapeutic mechanisms. Lower plasma levels and decreased responsiveness of SP possibly represent the enhanced stress sensitivity in primary hypertension.
J Cardiovasc Pharmacol 1987
PMID:Substance P in human essential hypertension. 245 74

To define the neurochemical substrates underlying cardiovascular regulatory mechanisms in the canine dorsal medulla, we characterized immunocytochemically the organization of substance P (SP) in the dorsomedial medulla. Substance P immunoreactivity was the most dense in the dorsal nucleus tractus solitarii (nTS). Varicose fibers and cells containing this neuropeptide were localized in the dorsal motor nucleus of the vagus (dmnX) and nucleus commissuralis. A few scattered fibers were observed within the area postrema. The distribution of this peptide suggests a topographical organization within the dorsomedial medulla of the dog that is closely related to the cytoarchitectural organization. In addition, the patterns of SP immunoreactivity overlap the distribution of vagal afferent fibers. These observations are discussed in relation to the possible function of SP in the dorsomedial medulla.
J Cardiovasc Pharmacol 1987
PMID:The distribution of substance P in the canine dorsomedial medulla. 245 85

The vascular neuromuscular junction is described and the terms neuromodulation and cotransmission defined. Two main types of interaction between peptide and nonpeptide neurotransmitter substances during the local control of blood flow are distinguished. The first concerns the interacting roles of peptides and nonpeptides that coexist in, and are released from, perivascular nerve varicosities. Examples include the interactions of neuropeptide Y (NPY) with noradrenaline (NA) and adenosine 5'-triphosphate (ATP) released from some sympathetic nerves; vasoactive intestinal polypeptide (VIP) with acetylcholine (ACh) released from some parasympathetic nerves; and NPY and 5-hydroxytryptamine (5-HT) released from intracardiac neurones supplying coronary vessels. Possible interactions of substance P (SP) and calcitonin gene-related peptide (CGRP) with ATP released from some primary afferent sensory nerves are also considered. The second type of interaction concerns vascular neurotransmitters and locally released agents such as histamine, prostanoids, and bradykinin. Finally, a hypothesis is put forward in which it is suggested that peptides and nonpeptides released from endothelial cells during hypoxia lead to protective vasodilatation via receptors on the endothelium, while these substances released from perivascular nerves during different physiological circumstances usually constrict the blood vessel via receptors on the smooth muscle cells.
J Cardiovasc Pharmacol 1987
PMID:Mechanisms of interaction of peptide and nonpeptide vascular neurotransmitter systems. 245 95


<< Previous 1 2 3 4 5 6 7 8 9 Next >>